JPRN-UMIN000021215已完成未知
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study on Anti-Allergic Effects of Continuous Ingestion of Lactococcus lactis subsp. cremoris YRC3780 - Anti-Allergic Effects of Continuous Ingestion of Lactococcus lactis subsp. cremoris YRC3780
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Subjects who have a past history of serious allergic reactions (anaphylaxis, etc.). 2. Subjects with acute rhinitis, sinusitis, nasal polyps, hypertrophic rhinitis and/or severely deviated nasal septum, etc. 3. Subjects with bronchial asthma. 4. Subject who are under immunotherapy such as specific desensitization therapy. 5. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, disorder of endocrine and metabolism or affected with infectious diseases which are required to report to the authorities. 6. Subjects who have a major surgical history related to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 7. Subjects with abnormal blood pressure or hematological data. 8. Subjects with serious anemia. 9. Pre- or post-menopausal women with complaints of obvious physical changes. 10. Subjects with a history of allergy to medicine and/or food (especially milk and corn). 11. Subjects who regularly take drugs which may affect evaluation of the current study (antihistamines, anti-allergic drugs, steroids, vasoconstrictors, anti-inflammatory drugs, anti-rheumatic drugs, antibiotics, immunosuppressive drugs and/or lactobacillus preparation, etc.). 12. Heavy smokers, alcohol addicts or subjects with irregular lifestyle. 13. Subjects who donated either 400ml whole blood within 12 weeks or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to the current study. 14. Pregnant or lactating women or women expect to be pregnant during the study. 15. Subjects who participate in other clinical trials within the last one month prior to this study. 16. Any other medical reasons judged by the principal investigator.
研究者
相似试验
进行中（未招募）
1 期
A study to test the effectiveness and safety of test product BIIB092 compared to placebo in participants with progressive supranuclear palsy, arare and progressive condition that can cause problems with balance, movement, vision, speech and swallowingProgressive supranuclear palsyMedDRA version: 21.1Level: PTClassification code 10036813Term: Progressive supranuclear palsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002554-21-ITBIOGEN IDEC RESEARCH LIMITED490
进行中（未招募）
1 期
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabMedDRA version: 19.0Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersAcute coronary syndromeEUCTR2011-005698-21-PLsanofi-aventis Recherche & Développement18,600
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of MigraineProphylaxis of migraine with or without aura, in patients with a diagnosis of at least 1-year duration.MedDRA version: 6.1Level: PTClassification code 10027607EUCTR2004-004162-33-ITJANSSEN-CILAG
进行中（未招募）
1 期
A study of Baricitinib in patients with LupusSystemic Lupus Erythematosus (SLE)MedDRA version: 21.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2017-005026-37-HREli Lilly and Company825
已完成
3 期
This study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.CTRI/2010/091/002997Johnson Johnson Ltd720